AllianceBernstein’s Travere Therapeutics TVTX Stock Holding History

AllianceBernstein’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.5M	Buy	143,817 +18,748	+15%	+$560K	﹤0.01%	1493
2025 Q4	$4.78M	Sell	125,069 -197,046	-61%	-$6.41M	﹤0.01%	1564
2025 Q3	$7.7M	Sell	322,115 -21,746	-6%	-$409K	﹤0.01%	1333
2025 Q2	$5.09M	Sell	343,861 -74,736	-18%	-$1.24M	﹤0.01%	1474
2025 Q1	$7.5M	Buy	418,597 +347,967	+493%	+$7.06M	﹤0.01%	1293
2024 Q4	$1.23M	Hold	70,630	–	–	﹤0.01%	2223
2024 Q3	$988K	Hold	70,630	–	–	﹤0.01%	2337
2024 Q2	$581K	Buy	70,630 +10	+0%	+$67	﹤0.01%	2594
2024 Q1	$544K	Hold	70,620	–	–	﹤0.01%	2552
2023 Q4	$635K	Hold	70,620	–	–	﹤0.01%	2489
2023 Q3	$631K	Hold	70,620	–	–	﹤0.01%	2459
2023 Q2	$1.08M	Buy	70,620 +11,300	+19%	+$206K	﹤0.01%	2239
2023 Q1	$1.33M	Hold	59,320	–	–	﹤0.01%	2089
2022 Q4	$1.25M	Sell	59,320 -13	-0%	-$275	﹤0.01%	2170
2022 Q3	$1.46M	Hold	59,333	–	–	﹤0.01%	2089
2022 Q2	$1.44M	Buy	59,333 +13	+0%	+$327	﹤0.01%	2152
2022 Q1	$1.53M	Buy	59,320 +100	+0.2%	+$2.65K	﹤0.01%	2238
2021 Q4	$1.84M	Hold	59,220	–	–	﹤0.01%	2194
2021 Q3	$1.44M	Sell	59,220 -4,300	-7%	-$79K	﹤0.01%	2351
2021 Q2	$927K	Sell	63,520 -77,160	-55%	-$1.52M	﹤0.01%	2563
2021 Q1	$3.51M	Buy	140,680 +77,160	+121%	+$2.13M	﹤0.01%	1770
2020 Q4	$1.73M	Buy	63,520 +7,800	+14%	+$182K	﹤0.01%	2069
2020 Q3	$1.03M	Buy	55,720 +6,600	+13%	+$128K	﹤0.01%	2174
2020 Q2	$1M	Buy	49,120 +2,700	+6%	+$43K	﹤0.01%	2202
2020 Q1	$677K	Hold	46,420	–	–	﹤0.01%	2215
2019 Q4	$659K	Hold	46,420	–	–	﹤0.01%	2434
2019 Q3	$538K	Sell	46,420 -59,190	-56%	-$978K	﹤0.01%	2513
2019 Q2	$2.12M	Hold	105,610	–	–	﹤0.01%	1940
2019 Q1	$2.39M	Sell	105,610 -3,000	-3%	-$66.3K	﹤0.01%	1798
2018 Q4	$2.46M	Hold	108,610	–	–	﹤0.01%	1715
2018 Q3	$3.12M	Hold	108,610	–	–	﹤0.01%	1623
2018 Q2	$2.96M	Sell	108,610 -152,860	-58%	-$4.07M	﹤0.01%	1645
2018 Q1	$5.85M	Buy	261,470 +61,000	+30%	+$1.45M	﹤0.01%	1132
2017 Q4	$4.22M	Buy	200,470 +25,000	+14%	+$571K	﹤0.01%	1325
2017 Q3	$4.37M	Buy	175,470 +77,450	+79%	+$1.71M	﹤0.01%	1297
2017 Q2	$1.9M	Buy	98,020 +50,000	+104%	+$907K	﹤0.01%	1886
2017 Q1	$886K	Sell	48,020 -82	-0.2%	-$1.6K	﹤0.01%	2299
2016 Q4	$911K	Buy	48,102 +82	+0.2%	+$1.68K	﹤0.01%	2305
2016 Q3	$1.07M	Hold	48,020	–	–	﹤0.01%	2192
2016 Q2	$855K	Sell	48,020 -3,610	-7%	-$58.4K	﹤0.01%	2298
2016 Q1	$705K	Hold	51,630	–	–	﹤0.01%	2271
2015 Q4	$996K	Hold	51,630	–	–	﹤0.01%	2127
2015 Q3	$1.05M	Buy	51,630 +820	+2%	+$24.3K	﹤0.01%	2145
2015 Q2	$1.68M	Buy	50,810 +36,600	+258%	+$1M	﹤0.01%	1941
2015 Q1	$340K	Buy	14,210 +4,600	+48%	+$70.1K	﹤0.01%	2633
2014 Q4	$118K	Sell	9,610 -4,600	-32%	-$47.6K	﹤0.01%	2952
2014 Q3	$128K	Hold	14,210	–	–	﹤0.01%	2898
2014 Q2	$167K	Buy	14,210 +12,400	+685%	+$168K	﹤0.01%	2869
2014 Q1	$38K	Buy	+1,810	New	+$27.8K	﹤0.01%	3152

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein's TVTX Position: Q1 2026 in Review

AllianceBernstein increased its Travere Therapeutics (TVTX) stake by 15% in Q1 2026, buying an estimated $560K and bringing the position to 143,817 shares worth $5.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1493.

AllianceBernstein first reported a position in TVTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $7.7M in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

AllianceBernstein held 143,817 shares of Travere Therapeutics worth $5.5M as of Q1 2026.
AllianceBernstein bought 18,748 Travere Therapeutics shares in Q1 2026, an estimated $560K.
Travere Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1493 holding.
AllianceBernstein first reported a position in Travere Therapeutics in Q1 2014 and has held it in 49 quarters since.
AllianceBernstein's Travere Therapeutics position peaked at $7.7M in Q3 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.